Miglitol tablets are enjoying renewed attention as clinicians seek affordable options to blunt postprandial glucose excursions in type 2 diabetes. As a fasting-active alpha-glucosidase inhibitor, miglitol slows carbohydrate breakdown in the gut, offering a complementary mechanism to metformin or basal insulin. The current trend is fueled by cost pressures and the growing demand for strategies that address post-meal spikes without escalating hypoglycemia risk. With several markets embracing generic production, miglitol is positioned as a practical add-on in resource-constrained settings and in payer-driven tiered formularies. The conversations now span dosing strategies, patient selection, and adherence-where real-world experience matters as much as pharmacology.
Read More: https://www.360iresearch.com/library/intelligence/miglitol-tablets